Navigation Links
Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
Date:4/9/2012

th.com.  Before you invest, you should read the preliminary prospectus supplement and the base prospectus and other documents Genesis Biopharma has filed or will file with the SEC for more complete information about Genesis Biopharma and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Genesis Biopharma, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including market conditions, risks associated with the cash requirements of the company's business a
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
2. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
3. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
4. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
5. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
6. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
7. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
8. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
9. Genesis Biopharma Names David Voyticky to Board of Directors
10. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
11. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , , , 77.6.6 Sample cooling ... If sensitive samples should remain cooled until the PCR takes place, the , ... ways: , , , ... Adapt an initial program and connect via a "LINK" command. , ...
... , , , 7.6.4 Long PCR , ... programmed as desired with every temperature , command, enables a , ... , With Long PCR, this function can be ... elongation. , , ...
... , , , There is obviously ... to all PCR amplifications. For example, , depending on the ... of the PCRs can differ from each other. Finding the optimal or the , ... and efficient amplification of a specific target. , ...
Cached Biology Technology:7 Programming 2PCR Optimization 2PCR Optimization 3
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... two human beings are the same. Although we all ... many places. And since genes provide the blueprint for ... in protein function. But what impact does this diversity ... Universitaet Muenchen (TUM) have investigated how protein function is ...
... and wastewater managers are missing substantial opportunities to save ... (Sept. 4) by Water in the West, a research ... Nexus: A Literature Review," also identifies the amount of ... oil and coal, and to generate electricity. , The ...
... Researchers have known for some time that the blood vessels ... the body are more than just bodily pipelines. Arterioles and ... regulating the flow of the blood they,re carrying. Biomedical engineers ... mathematical model that explains just how they do it. ...
Cached Biology News:Wide range of differences, mostly unseen, among humans 2Report reveals missed opportunities to save water and energy 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... Adaptor encodes a T7 promoter, lac ... translation initation codon and an N-terminal GST•Tag ... reported to enhance the production and in ... partners. The GST•Tag is a multi-purpose tag ...
Biology Products: